López-Menduiña M, Martín A I, Castillero E, Villanúa M A, López-Calderón A
Department of Physiology, Faculty of Medicine, Complutense University, Avda. Complutense s/n. 28040 Madrid, Spain.
Growth Horm IGF Res. 2012 Feb;22(1):22-9. doi: 10.1016/j.ghir.2011.12.003. Epub 2012 Jan 13.
Adjuvant-induced arthritis is an experimental model of rheumatoid arthritis that inhibits the GH-IGF-I axis and decreases body weight gain and muscle mass. Although chronic GH or IGF-I treatment increases body weight gain in arthritic rats, muscle resistance to GH and IGF-I is a very common complication in inflammatory diseases. In this study we examine the effect of short-term administration of rhGH and rhIGF-I on liver and muscle IGF-I, IGFBP-3 and -5 as well as on the ubiquitin-ligases MuRF1 and atrogin-1 in the muscle of arthritic rats.
Arthritis was induced in adult male Wistar rats by an intradermal injection of 4 mg of Freund's adjuvant. Fifteen days after adjuvant injection, 300 μg/kg of rhGH or 200 μg/kg of rhIGF or saline was administrated 18 and 3h before decapitation. A pair-fed group injected with saline was included in order to discard a possible effect of decreased food intake. Gene expression of IGF-I, GHR, IGFBP-3, IGFBP-5, atrogin-1 and MuRF1 were quantified using RT-PCR. In serum, IGF-I was measured by radioimmunoassay (RIA) and IGFBP-3 by ligand blot.
Arthritis decreased serum IGF-I and IGF mRNA in liver (P<0.05), but not in skeletal muscle. In arthritic rats, rhGH increased serum IGF-I and liver IGF-I mRNA similar to the levels of pair-fed rats. Arthritis increased atrogin-1, MuRF1, IGFBP-3 and IGFBP-5 mRNA in muscle (P<0.01). IGFBP-3 mRNA was downregulated by rhIGF-I, but not by rhGH, administration in control and arthritic rats (P<0.05). Administration of rhGH and rhIGF-I increased IGFBP-5 in the gastrocnemius of arthritic rats.
Short-term rhGH and rhIGF-I administration was found to increase muscle IGFBP-5 mRNA, whereas only rhIGF-I administration decreased muscle IGFBP-3 mRNA in control and arthritic rats. These data suggest that arthritis does not induce GH or IGF-I resistance in skeletal muscle.
佐剂性关节炎是类风湿性关节炎的一种实验模型,该模型会抑制生长激素-胰岛素样生长因子-I(GH-IGF-I)轴,并降低体重增加和肌肉质量。尽管长期使用生长激素(GH)或胰岛素样生长因子-I(IGF-I)治疗可增加关节炎大鼠的体重,但在炎症性疾病中,肌肉对GH和IGF-I产生抵抗是非常常见的并发症。在本研究中,我们检测了短期给予重组人生长激素(rhGH)和重组人胰岛素样生长因子-I(rhIGF-I)对关节炎大鼠肝脏和肌肉中IGF-I、胰岛素样生长因子结合蛋白-3(IGFBP-3)和-5以及肌肉中泛素连接酶肌肉萎缩相关蛋白1(MuRF1)和肌肉萎缩特异性基因1(atrogin-1)的影响。
通过皮内注射4mg弗氏佐剂诱导成年雄性Wistar大鼠患关节炎。佐剂注射15天后,在断头前18小时和3小时分别给予300μg/kg的rhGH或200μg/kg的rhIGF-I或生理盐水。设置一对注射生理盐水的配对喂养组,以排除食物摄入量减少可能产生的影响。使用逆转录聚合酶链反应(RT-PCR)对IGF-I、生长激素受体(GHR)、IGFBP-3、IGFBP-5、atrogin-1和MuRF1的基因表达进行定量分析。采用放射免疫分析法(RIA)测定血清中IGF-I水平,采用配体印迹法测定IGFBP-3水平。
关节炎会降低肝脏中的血清IGF-I和IGF mRNA水平(P<0.05),但不会降低骨骼肌中的这些水平。在关节炎大鼠中,rhGH可增加血清IGF-I和肝脏IGF-I mRNA水平,使其与配对喂养大鼠的水平相似。关节炎会增加肌肉中atrogin-1、MuRF1、IGFBP-3和IGFBP-5的mRNA水平(P<0.01)。在对照大鼠和关节炎大鼠中,rhIGF-I给药可下调IGFBP-3 mRNA水平,但rhGH给药则无此作用(P<0.05)。给予rhGH和rhIGF-I可增加关节炎大鼠腓肠肌中的IGFBP-5水平。
研究发现,短期给予rhGH和rhIGF-I可增加肌肉中IGFBP-5 mRNA水平,而在对照大鼠和关节炎大鼠中,只有给予rhIGF-I可降低肌肉中IGFBP-3 mRNA水平。这些数据表明,关节炎不会在骨骼肌中诱导GH或IGF-I抵抗。